Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …

Background Both inhaled steroids (ICS) and long‐acting beta 2‐agonists (LABA) are used in
the management of chronic obstructive pulmonary disease (COPD). This updated review …

We performed a meta-analysis to compare the impact of triple combination therapy with
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …

Background Randomized controlled trials (RCTs) indicate that long-acting bronchodilator
combinations, such as β2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable …

When there are no randomised clinical trials directly comparing all relevant treatment
options, an indirect treatment comparison via meta-analysis of the available clinical …

Background This study aims to compare the effects of single inhaler triple therapy comprised
of inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and long-acting …

Background Both long‐acting beta 2‐agonists (LABA) and inhaled corticosteroids (ICS)
have been recommended in guidelines for the treatment of chronic obstructive pulmonary …

Triple inhaled therapy for chronic obstructive pulmonary disease (COPD) consists of an
inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic …

Despite several long-acting β 2-adrenoceptor agonist (LABA)/long-acting muscarinic
antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved for the treatment …

Objectives The aim of this study was to assess the current evidence for long-acting β2-
agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) …